Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 studyResearch in context

Summary: Background: Tazemetostat, the first enhancer of zeste homolog 2 (EZH2) inhibitor approved by the U.S. Food and Drug Administration, has shown efficacy in a global population with relapsed or refractory (R/R) follicular lymphoma (FL). This phase 2 study was primarily designed as a registrat...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Junning Cao, Guangliang Chen, Lihua Qiu, Liling Zhang, Ming Jiang, Ying Cheng, Qiaohua Zhang, Lihong Liu, Ping Li, Yuerong Shuang, Huaqing Wang, Hongwei Xue, Huijing Wu, Meifang Zheng, Keshu Zhou, Zhiming Li, Hongmei Jing, Wei Yang, Zunmin Zhu, Wenyu Li, Jiaxuan Wangwu, Heyu Huang, Qiantao Jia, Dongmei Chen, Songhua Fan, M. Ming Shi, Weiguo Su
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-09-01
coleção:	EClinicalMedicine
Assuntos:	Follicular lymphoma EZH2 inhibitor Bridging study Tazemetostat Chinese
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589537025003311
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!